3 Lesser-Known Biotech Stocks That Are Surging

The consensus revenue estimate for the year ended December 31, 2020, is $47.1 million, representing a 262.6% year-over-year increase. Its EPS for the period is expected to decline 3.6% to $3.14.

ZLAB ended yesterday’s trading session at $184.7, surging 247.8% over the past year. Over the past six months, the stock surged 120.8%.

ZLAB’s POWR Ratings reflect this promising outlook. It has an overall rating of “Strong Buy” with an “A” for Trade Grade, Buy & Hold Grade, and Peer Grade and a “B” for Industry Rank. Among China stocks, it is ranked 12th of 103.

More Great Investing Ideas?

“MUST OWN” Growth Stocks for 2021

How to Outperform the Stock Market?

7 Best ETFs for the NEXT Bull Market

5 WINNING Stocks Chart Patterns

BGNE shares were trading at $367.98 per share on Wednesday morning, up $11.30 (+3.17%). Year-to-date, BGNE has gained 42.41%, versus a 2.36% rise in the benchmark S&P 500 index during the same period.

1 2 3 4
View single page >> |

Disclaimer: Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use, please ...

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.